[Piprozoline in clinical trials (author's transl)]

Area of Science:

• Pharmacology
• Gastroenterology
• Clinical Medicine

Background:

• Upper abdominal disorders present diagnostic challenges.
• Piprozoline (Gö 919, Problin) is a choleretic substance investigated for therapeutic potential.
• Previous experimental findings require validation through extensive clinical data.

Purpose of the Study:

• To compare experimental findings on piprozoline with extensive clinical trial results.
• To evaluate the tolerance and efficacy of piprozoline in a large patient cohort.
• To confirm the therapeutic benefits of piprozoline in patients with biliary and intestinal disorders.

Main Methods:

• Open and controlled clinical trials were conducted.
• A total of 1545 patients and 1807 courses of therapy were involved.
• Data from previous experimental studies were compared with comprehensive clinical investigations.

Main Results:

• Piprozoline therapy showed definite therapeutic benefits, confirming experimental findings.
• Significant improvement was observed in symptoms like bloating, nausea, constipation, and fat intolerance.
• Serum bilirubin and alkaline phosphatase levels tended to normalize more effectively with piprozoline compared to placebo.
• The drug was effective in treating conditions primarily of biliary origin.
• The rate of side-effects associated with piprozoline was found to be insignificant.

Conclusions:

• Piprozoline is a therapeutically beneficial choleretic substance for gall-bladder diseases and intestinal disorders.
• The clinical data confirm the efficacy and good tolerance of piprozoline.
• Piprozoline offers a favorable risk-benefit profile for managing upper abdominal complaints.